Browsed by
Tag: Overweight

Can hormones predict the possibility of weight loss?

Can hormones predict the possibility of weight loss?

In addition to being one of the world’s greatest killers, obesity is linked to several medical disorders. The majority of people who do succeed in losing excess weight do so only to gain it back, which frequently frustrates attempts to shed excess weight through lifestyle changes.

Understanding the complicated function that hormones play in this process may aid in the creation of effective long-term treatments for obesity.

Now that higher levels of the hormone neurotensin have been connected to greater weight loss maintenance in obese individuals, this information provides another hint as to how to rebound weight gain might be controlled.

It has long been understood that while many people who struggle with overweight or obese can lose excess weight through lifestyle changes like diet and exercise, it can be difficult for many of them to keep it off.

The World Health Organisation (WHO) views obesity as an epidemic since it causes more than 4 million deaths annually. Many of these fatalities are thought to be preventable with weight loss. For instance, it has been demonstrated that a weight loss of 5–7% can halt or delay the onset of type 2 diabetes.

Sadly, up to 80% of people who lose weight through diet and exercise gain back every bit of the weight they previously did. In the past, this weight increase has been attributed to a lack of self-control or a failure to follow weight maintenance plans.

A higher level of the hormone neurotensin may be associated with a superior capacity to maintain weight loss in obese people who have recently lost weight, according to the most recent research, which gives a fresh explanation.

Do we regain weight after weight loss?

The assumption that the body would return to a predetermined weight despite weight loss or growth has been proposed as one theory to explain why people experience rebound weight gain.

Bariatric surgeon Dr. Mir Ali of Orange Coast Medical Centre in Fountain Valley, California, who also serves as the center’s medical director, explained:

According to the set point theory, there is a weight that your body prefers to maintain at all times (within 5 to 10 pounds). This set point can be influenced by a variety of factors, including age, heredity, sex, health issues, and degree of activity. But it’s unclear what mechanisms might be at work in this observation.

The importance of hormones in hunger regulation has just recently come to light, despite the WHO reporting a rise in the number of persons with obesity starting in the 1970s. Only in 1999 was ghrelin, a hormone that promotes the desire to eat, separated and identified. Its ability to control hunger, fat storage, and energy regulation is now well documented. It also has interactions with other hormones like insulin which are important in regulating energy and storing fat.

Researchers have postulated that the fact that ghrelin levels tend to increase after weight reduction brought on by diet and exercise may be the cause of “rebound weight gain.” Contrarily, after bariatric surgery, which has a lower rate of rebound weight gain than diet and exercise-based therapies, levels of this hormone drop.

Less than 20 years ago, in 2004, researchers found that ghrelin and leptin, a hormone that controls satiety and long-term energy balance, interact. Since then, it has been shown that obese individuals have leptin resistance, which makes them less susceptible to its appetite-suppressing benefits.

looking into the neurotensin hormone

Recently, the focus has shifted to a different hormone termed neurotensin and its potential contribution to weight gain following weight reduction. The brain and intestines both generate this hormone. Previous studies have demonstrated that neurotensin levels rise following bariatric surgery, much like other hormones that control hunger and energy expenditure.

According to Dr. Gina Leinninger, an associate professor of physiology at Michigan State University who studies how the body manages its energy and how it affects obesity in people.

The possibility that neurotensin could modify body weight has drawn increasing attention. We were aware from earlier studies that neurotensin could cause animal models to eat less and move around more, two behaviors that might help them lose weight.

Higher neurotensin levels following meals may be associated with an individual’s likelihood of maintaining weight loss, according to a group of Danish researchers. In mice and obese adults, they also demonstrated a drop in neurotensin levels following weight loss.

Effects of neurotensin on preserving weight loss

8 obese mice were kept on a regular diet as controls, while 9 obese mice were placed on a calorie-restricted diet for 8 days. After the animals were put to sleep, the scientists collected samples from the duodenum, jejunum, ileum, and proximal colon to examine the levels of neurotensin expressed in those regions.

The goal of the calorie-restricted diet for mice was to promote weight loss that was comparable to what was shown in the 8-week human research.

The amounts of neurotensin in the jejunum region of the small intestine were much lower in the mice whose access to food was restricted, the researchers discovered.

The next step was to examine how a group of 42 obese patients responded to an extremely low-calorie diet plan of roughly 800 calories per day for eight weeks. Following this regimen, participants lost 12.3 kg on average. Participants underwent testing to see how their leptin, insulin, ghrelin, and neurotensin levels changed in the three hours following a meal after these 8 weeks.

For a further 52 weeks, researchers gave this group of participants instructions to eat a diet with a calorie restriction (600 fewer calories than their daily requirements).

Researchers examined data for a subcohort of participants from both groups—those who had lost over 3% weight during the maintenance period and those who had gained at least 5% of their initial weight loss—in order to examine the effect of hormones on weight loss maintenance.

After the initial 8-week weight loss phase, they discovered that those who had initially displayed a higher level of neurotensin in the three hours following a meal were more likely to have continued to lose weight during the maintenance phase.

What does this indicate for the management of obesity?

The Metabolism research is the first to link variations in circulating neurotensin to better/more sustained weight loss results in humans, and it suggests that (in the future), manipulating the neurotensin system might be helpful to support and/or optimise weight reduction. Dr. Leinninger acknowledged that there is still much to learn before that objective can be met.

In her own research, Dr. Leinninger examined the areas of the brain that neurotensin affects and if these areas are involved in the management of energy and obesity. That will be the focus of the following research steps.

How neurotensin can regulate weight and, more particularly, where in the body it acts, are the next great unanswered mysteries. We have some promising results in my lab’s investigation into how and where in the brain neurotensin can affect body weight, she said.

REFERENCES:

For Weight loss medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=20

Trial Obesity therapy can lead to nausea-less weight loss.

Trial Obesity therapy can lead to nausea-less weight loss.

Researchers have created a new class of peptides that might offer gastric bypass surgery’s advantages without requiring intrusive procedures. According to recent research, these peptides helped obese rats lose a large amount of weight and lower their blood glucose levels.

The injectable substances minimise eating while also increasing calorie burn, and they do so without the side effects of nausea and vomiting that are frequently associated with modern weight reduction and diabetic medications.

Diabetes and obesity are both major public health issues, with the former being one of the main risk factors for the latter. A good therapeutic option is bariatric surgery, which includes the gastric bypass, gastric sleeve, and gastric band. It can lead to long-term weight loss and even the remission of diabetes.

These procedures, nevertheless, have significant risks, are not appropriate for everyone, and are not easily accessible to the majority of people. Therefore, some researchers propose that a different therapeutic choice would be to treat metabolic problems with medication that mimics the long-term benefits of surgery.

Obesity

According to the National Institutes of Health, obesity and being overweight are chronic illnesses that are widespread in the United States.

These problems can worsen a variety of other medical conditions and are associated with heart disease, diabetes, and cancer.

The following are some of the factors that contribute to obesity:

  • eating habits, such as consuming meals and drinks that are high in calories but poor in nutrients
  • sleep deprivation
  • absence of exercise
  • Many drugs, including those prescribed for diabetes, depression, or high blood pressure
  • genealogy and genetics

Overweight or obesity affects over three-fourths of US adults over the age of 20. Obesity affects 20% of kids between the ages of 2 and 19 years.

Body mass index (BMI) is used by medical practitioners to check for overweight and obesity. The formula is: Height squared divided by weight (in kilos) (in meters.) Online BMI calculators abound, one of which is provided by the CDC.

Sood told that he would like future research on weight loss to evaluate both weight loss and body composition. “We just lack sufficient knowledge to determine whether patients taking gut hormone agonists for weight loss are mostly losing fat or a mixture of fat and muscle,” says the researcher (the latter is more likely). To age properly and retain a strong metabolism as we age, losing muscle would be counterproductive.

Gut peptides

Some patients who have had gastric bypass surgery benefit from specific health advantages linked to adjustments in the gut’s hormone output.

The hormones in question, such as peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), signal fullness, curb hunger, and aid in blood sugar regulation.

Targeting GLP-1 receptors in the pancreas and brain, scientists have created medications that seek to mimic these effects.

These medications have been effective in managing type 2 diabetes and weight loss. There is a need for better solutions with fewer side effects because some people are unable to handle the negative effects of these medications, and studies show that roughly half of those who start taking them stop within a year.

Better option

To meet this demand, a group led by scientists from Syracuse University in New York has created a novel peptide. On March 26–30, they discussed their most current findings at the ACS Spring 2023 meeting.

The researchers suggest that an alternate treatment for those with metabolic issues would be a substance that matches the long-term advantages of gastric bypass surgery.

Several strategies have been devised by researchers to alleviate the negative effects of medications that only target one hormone receptor in the stomach. Designing medications to interact with several receptor types is one approach.

In a prior investigation, the group produced a peptide named GEP44 that activates two peptide YY receptors and one glucagon-like peptide-1 receptor.

When this substance was tested on obese rats, it was discovered that the animals that received it consumed up to 80% less food than usual and on average lost 12% of their body weight over the course of the 16-day experiment.

In a recent study, they compared the novel peptide GEP44’s efficacy in treating obesity to that of the medication liraglutide.

According to the study, rats given GEP44 lost more weight than rats given liraglutide. When tested on rats and shrews, GEP44, unlike liraglutide, did not exhibit any signs of nausea or vomiting.

According to the researchers, this might be as a result of GEP44 activating a number of receptors, which might stop the intracellular signalling cascade that results in these symptoms.

Weight loss and high energy expenditure

This study also suggests that the weight reduction brought on by GEP44 is a result of increased energy expenditure rather than just a decrease in food consumption. The manifestation of this rise in energy expenditure can take several forms, including an increase in heart rate, body temperature, or physical activity.

By directing glucose into muscle tissue to be used as fuel and by transforming specific pancreatic cells into cells that produce insulin, peptide treatments like GEP44 not only aid in weight reduction but also aid in lowering blood sugar levels.

GEP44 must be administered numerous times daily to maintain its effectiveness because it has a brief half-life in the body. The team has created a novel peptide, however, that requires only one or two injections per week and has a far longer lifespan.

The researchers discovered that rats treated with this novel molecule continue to lose weight even after the treatment has ceased, which is unusual for medications currently on the market that have been licenced to treat obesity.

“Obesity is obviously an increasing epidemic worldwide,” Dr. Becca Krukowski, professor of public health sciences at the University of Virginia and a non-participant in this study, told us.

What does it implies?

Although these are preliminary results in lab animals, Dr. Krukowski said that “over time, our research may lead to novel drugs that are safe and beneficial for patients.” But before being widely administered, this medication would need to go through the deliberate deliberate slow and thorough multi-stage and multi-year testing process, she warned.

However, if this treatment characteristic was verified in trials with humans, Krukowski continued, “the possible lack of weight regain after ceasing treatment would be extremely interesting.”

Both positive and negative impacts from this research, according to Bishoff, are possible. “The benefits being that patients can take lesser doses of medications that can deliver desired results while reducing nausea and vomiting side effects.

On the other hand, it’s possible that weight loss medications lower caloric intake to the point of malnutrition or deficiency. In the end, additional study will be required, which may take several years.

Although there may be some medical advantages to weight reduction medications, it’s crucial that patients understand they shouldn’t be used as a substitute for a healthy lifestyle. They can be viewed as a tool as opposed to a fix. When controlling weight and diabetes, eating a variety of well-balanced meals, sticking to daily caloric goals, and exercising frequently should always be encouraged, according to Haley Bishoff.

REFERENCES:

For Weight loss medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=20